Johnson & Johnson Announces TREMFYA®'s Success in Inhibiting Joint Damage in Psoriatic Arthritis, Setting New Standards in IL-23 Inhibitor Efficacy
Reuters
Jun 11, 2025
Johnson & Johnson Announces TREMFYA®'s Success in Inhibiting Joint Damage in Psoriatic Arthritis, Setting New Standards in IL-23 Inhibitor Efficacy
Johnson & Johnson has announced findings from the Phase 3b APEX study demonstrating the efficacy of TREMFYA® (guselkumab) in treating active psoriatic arthritis. The study results, presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, show that TREMFYA® significantly reduced signs and symptoms of the disease and inhibited the progression of joint structural damage at 24 weeks compared to placebo. More than 40% of patients treated with TREMFYA® achieved ACR50, a measure of improvement in joint symptoms, by Week 24. Additionally, a higher proportion of TREMFYA®-treated patients achieved clear or almost clear skin compared to those receiving placebo. The safety profile of TREMFYA® remains consistent with previous studies, with no new safety signals identified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: NY04448) on June 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.